Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients
Authors
Keywords
Diffuse large B cell lymphoma, Serum soluble programed death ligand 1, End of treatment response, Positron emission tomography-computed tomography
Journal
CLINICAL AND EXPERIMENTAL MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-06
DOI
10.1007/s10238-018-0506-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast
- (2017) Elizabeth D Thompson et al. MODERN PATHOLOGY
- Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
- (2017) Cristina Ilcus et al. OncoTargets and Therapy
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Genomic alterations of theJAK2andPDLloci occur in a broad spectrum of lymphoid malignancies
- (2016) Katrien Van Roosbroeck et al. GENES CHROMOSOMES & CANCER
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma
- (2014) Abhimanyu Ghose et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Diffuse large B-cell lymphoma
- (2013) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-α
- (2009) Atsuhiko Hikita et al. Biochemistry and Cell Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search